logo

For the Inventor, By the Inventor

New York, NY, United States of America

Beyondspring Pharmaceuticals, Inc.


USPTO Granted Patents = 21


Trademarks = 3

Forward Citations = 137

Loading Chart...
Loading Chart...

9 inventors (with patents filed for the assignee):

goldMedal Lan Huang (20 out of 23 patents)

silverMedal Ramon Mohanlal (8 out of 8 patents)

bronzeMedal George Kenneth Lloyd (8 out of 12 patents)

4.  Aniruddh Singh (4 out of 7 patents)

5.  Michel O Steinmetz (2 out of 2 patents)

6.  Santosh Ambadas Khedkar (2 out of 6 patents)

7.  Michael A Palladino (1 out of 24 patents)

8.  Yoshio Hayashi (1 out of 10 patents)

9.  James R Tonra (1 out of 1 patent)

10.  Michel O Steinmetz (0 patent)


21 patents:

1. 12458639 - Tubulin binding compounds and therapeutic use thereof (2025-11-04),
2. 12458638 - Method of stimulating neutrophil survival and reducing neutropenia (2025-11-04),
3. 12433886 - Composition and method for reducing neutropenia (2025-10-07),
4. 12377094 - Therapeutic compositions and methods for treating checkpoint inhibitor-resistant tumors using plinabulin-based combination therapies (2025-08-05),
5. 12024501 - Plinabulin compositions (2024-07-02),
6. 11918574 - Method of treating cancer associated with a RAS mutation (2024-03-05),
7. 11857522 - Compositions containing tucaresol or its analogs (2024-01-02),
8. 11786523 - Composition and method for reducing thrombocytopenia (2023-10-17),
9. 11633393 - Tubulin binding compounds and therapeutic use thereof (2023-04-25),
10. 11400086 - Method of reducing chemotherapy-induced neutropenia (2022-08-02),
11. 11254657 - Plinabulin compositions (2022-02-22),
12. 11229642 - Composition and method for reducing neutropenia (2022-01-25),
13. 11045467 - Method of treating cancer associated with a RAS mutation (2021-06-29),
14. 10912748 - Compositions containing tucaresol or its analogs (2021-02-09),
15. 10668063 - Method of treating cancer associated with a RAS mutation (2020-06-02),
Company Overview
Beyondspring Pharmaceuticals, Inc. is a biopharmaceutical company based in New York, specializing in the development of innovative therapies for cancer treatment. The organization focuses on advancing its proprietary drug candidates, particularly in the areas of immuno-oncology and supportive care, aiming to improve patient outcomes. With a commitment to addressing unmet medical needs, Beyondspring leverages cutting-edge research and technology to enhance the efficacy and safety of its therapeutic offerings.
Profile summary synthesized from public USPTO records and patent filings.

logo

Company Badge

USPTO Data Jan 1 1976 - Oct 13 2026

21 Patents

#388 in New York, NY

#921 in New York

#15,695 in US

#29,961 in the World

New York, NY (US)
New York, NY, United States of America

Beyondspring Pharmaceuticals, Inc.

Forward Citations = 137

9 inventors:

goldMedal Lan Huang (20 out of 23 patents)

silverMedal Ramon Mohanlal (8 out of 8 patents)

bronzeMedal George Kenneth Lloyd (8 out of 12 patents)

4.  Aniruddh Singh (4 out of 7 patents)

5.  Michel O Steinmetz (2 out of 2 patents)

IDiyas Innovation Intelligence. (2026). Company Patent Portfolio: Beyondspring Pharmaceuticals, Inc.. Retrieved from https://idiyas.com/company/beyondspring-pharmaceuticals

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…